Research summary, original research, 2019

Feasibility and safety of robotic PCI in China: first in man experience in Asia

Dou KF, Song CX, Mu CW, Yang WX, Zhu CG, Feng L, et al.. Journal of geriatric cardiology : JGC. 2019

Read the original paper

In plain language

In 10 patients at one Chinese centre, second-generation robotic percutaneous coronary intervention (PCI) was completed without manual conversion or major adverse events. Staff radiation dose was not measured, so this study does not show reduced exposure for the fluoroscopy team.

At a glance

Type of study
Original research, Case report or series
Who was studied
Patients, Interventional cardiologists
Size
n = 10 patients
Where
China
Summary based on
the full text

What it found

  • All 11 lesions in 10 patients were treated successfully with the second-generation robotic system, with no conversion to manual operation and no in-hospital major adverse cardiac events (MACE).

    Key figures: 11/11 (100%) clinical success

  • Fluoroscopy time and air kerma were numerically lower in later than early cases, but differences were not statistically significant.

    Key figures: fluoroscopy 20.3 ± 8.2 vs. 12.5 ± 4.6 min, P = 0.16; air kerma 1932 ± 978 vs. 1007 ± 70 mGy, P = 0.31

  • Mean procedure and fluoroscopy times across all cases were reported; live demonstration cases inflated times.

    Key figures: procedure time 57.7 ± 26.4 min; fluoroscopy 18.2 ± 8.0 min; air kerma 1681 ± 870 mGy

  • Operators worked seated in a radiation-shielded cockpit, but operator radiation dose was not measured in this study.

Limits to keep in mind

Single-centre series of 10 patients with two operators, no manual-PCI comparison group, and no measurement of staff or operator radiation dose.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.